机译:TLR7激动剂脯氨酸的脂质缀合可确保与脂质体阳离子佐剂制剂01(CAF01)共递送,但与非共轭份替代+ CAF01相比,不增强免疫稳定性
Aston Univ Sch Life &
Hlth Sci Birmingham W Midlands England;
Aston Univ Sch Life &
Hlth Sci Birmingham W Midlands England;
Univ Strathclyde Strathclyde Inst Pharm &
Biomed Sci 161 Cathedral St Glasgow G4 0RE Lanark Scotland;
Statens Serum Inst Dept Infect Dis Immunol Copenhagen Denmark;
Statens Serum Inst Dept Infect Dis Immunol Copenhagen Denmark;
Univ Strathclyde Strathclyde Inst Pharm &
Biomed Sci 161 Cathedral St Glasgow G4 0RE Lanark Scotland;
Cationic liposomes; TLR agonist; Resiquimod; Vaccine adjuvant; Tuberculosis; Biodistribution;
机译:TLR7激动剂脯氨酸的脂质缀合可确保与脂质体阳离子佐剂制剂01(CAF01)共递送,但与非共轭份替代+ CAF01相比,不增强免疫稳定性
机译:脂质缀合的TLR7激动剂的高效力需要纳米颗粒或脂质体配方
机译:小分子TLR7激动剂与二氧化硅纳米酚的缀合增强了佐剂活性
机译:脂质缀合的TLR7激动剂的高效力需要纳米颗粒或脂质体制剂
机译:TLR7激动剂脯氨酸的脂质缀合可确保与脂质体阳离子佐剂制剂01(CAF01)共递送,但与非共轭份替代+ CAF01相比,不增强免疫稳定性